Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nat Med. 2004 Sep;10(9):909-15.

Cancer immunotherapy: moving beyond current vaccines.

Author information

  • 1Surgery Branch of the Center for Cancer Research at the National Cancer Institute, Building 10, Room 2B42, 10 Center Drive, MSC 1502 Bethesda, Maryland 20892-1502, USA. sar@mail.nih.gov

Abstract

Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.

Comment in

PMID:
15340416
[PubMed - indexed for MEDLINE]
PMCID:
PMC1435696
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk